• Nabriva closes in on bringing new class of antibiotic to market pharmafile
    May 25, 2018
    Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could result in a newly approved antibiotic for doctors to utilise – a type of approval that are few and far between.
PharmaSources Customer Service